7/27/2022 7:26:11 AM
Alkermes plc (ALKS) Has Raised Its FY22 Revenue Estimate To $1,050 – $1,120 Mln From $1,000 – $1,090 Mln
7/27/2022 7:25:47 AM
Alkermes plc (ALKS) Has Raised Its FY22 EPS Estimate To 0.09 - 0.27 From -0.18 - 0.00
7/27/2022 7:04:58 AM
Alkermes Q2 GAAP Loss Per Share $0.18 And Non-GAAP EPS $0.06
7/6/2022 7:08:27 AM
Sarissa Capital Comments On Alkermes Annual Meeting; Supports New Alkermes Directors To Step Up
6/1/2022 7:01:40 AM
Alkermes Presents ARTISTRY-1 Data At 2022 ASCO Annual Meeting
5/27/2022 10:04:06 AM
Sarissa Capital Management Shocked By Alkermes' Sudden Announcement Of Its Slate Of Director Nominees
4/27/2022 7:03:37 AM
Alkermes Plc Q1 GAAP Loss Per Share $0.22; Non-GAAP EPS $0.12
2/17/2022 7:03:34 AM
Alkermes Presents New Data From Ongoing Phase 1/2 ARTISTRY-1 Trial For Nemvaleukin Alfa
2/16/2022 7:02:00 AM
Alkermes Plc Q4 GAAP EPS $0.01; Non-GAAP EPS $0.23
2/8/2022 7:01:25 AM
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study Of LYBALVI® In Patients Early In Illness
1/18/2022 7:03:29 AM
Alkermes To Present Data On Nemvaleukin Alfa At American Society Of Clinical Oncology Gastrointestinal Cancers Symposium